Filing Summary
Registrant: Kindly MD, Inc. The provided metadata identifies Nakamoto Inc., but the filing names Kindly MD, Inc. as the registrant. Form 8-K was dated June 5, 2024, reporting events beginning May 31, 2024. The company is an emerging growth company and trades on Nasdaq under KDLY and KDLYW.
Business Context and Reporting Period
The filing reports the entry into an underwriting agreement on May 31, 2024, for a public offering that closed on June 3, 2024. The filing does not provide operating results or a financial reporting-period income statement.
Offering and Key Financial Metrics
- The company sold 1,240,910 units at a public price of $5.50 per unit.
- Each unit included one common share, one tradeable five-year warrant to purchase one share, and one non-tradeable five-year warrant to purchase one-half share.
- The warrants have an exercise price of $6.33 per share.
- Total gross proceeds from the common-stock sale were $6,825,005.
- Net proceeds after underwriting commissions and expenses were $6,018,882.18.
- The offering created rights to acquire up to 1,861,365 shares through the warrants, excluding the Representative’s Warrants and any over-allotment securities.
- The company issued 83,639 warrants to WallachBeth Capital LLC, with a $6.33 exercise price, five-year term, and cashless exercise option.
- The underwriters received a 45-day over-allotment option for up to 186,136 shares and/or 186,136 tradeable warrants and/or 186,136 non-tradeable warrants. On June 3, 2024, the option was partially exercised for 76,538 of each warrant type.
The filing does not provide revenue, net income, earnings per share, cash flow, operating margins, total debt, cash balance, or post-offering liquidity metrics.
Material Changes Versus the Prior Comparable Period
- The transaction increased cash by net proceeds of approximately $6.0 million, before considering subsequent use of funds.
- The transaction increased outstanding common shares by 1,240,910 shares at closing and created substantial potential future dilution from warrants.
- The filing does not provide prior-period operating or balance-sheet data, so changes in revenue, profitability, cash flow, debt, or margins cannot be assessed.
Guidance, Outlook, Risks, and Unusual Items
- No quantitative financial guidance or business outlook is provided.
- Management furnished press releases containing forward-looking statements and cautioned that actual outcomes may differ materially because of risks, uncertainties, and assumptions.
- The offering is subject to customary representations, warranties, covenants, and indemnification obligations in favor of the underwriters.
- The warrants and the underwriters’ over-allotment option create potential future share dilution.
- The Warrant Agent Agreement with VStock Transfer, LLC governs registration, transfer, exercise, amendment procedures, and indemnification relating to the warrants.
- The offering was conducted under the company’s effective Form S-1 registration statement.
Important Facts for Investors to Verify
- Confirm the correct issuer, because the request metadata says Nakamoto Inc. while the filing identifies Kindly MD, Inc.
- Review the final capitalization table after issuance of the shares, warrants, Representative’s Warrants, and over-allotment securities.
- Verify the use of the approximately $6.02 million in net proceeds and the company’s cash runway.
- Assess the potential dilution from 1,861,365 warrant shares, 83,639 Representative’s Warrants, and the partially exercised over-allotment option.
- Review the full underwriting agreement, warrant forms, Warrant Agent Agreement, and related prospectus for exercise, adjustment, redemption, and anti-dilution provisions.
- Review subsequent filings for operating results, liquidity, debt, and any additional offering activity.